NCT00416065

Brief Summary

The purpose of this research is to evaluate the presence, location and intensity of FDG uptake in the large arteries using the new technology of fused PET/CT imaging and to compare FDG uptake with the presence of arterial calcifications as seen on the simultaneously acquired CT, in order to determine if FDG was increases incalcified plaque or in a different location in the arterial wall. we will also evaluate the relationship between FDG localization and future cardiovascular events in out patient population

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2004

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

December 26, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 27, 2006

Completed
Last Updated

December 27, 2006

Status Verified

November 1, 2006

First QC Date

December 26, 2006

Last Update Submit

December 26, 2006

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

  • the impact of the imaging modality on patient management

Secondary Outcomes (1)

  • the impact of the imaging modality on patient management

Interventions

PET/CT imagingDEVICE

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients referred for clinical FDG-PET/CT studies
  • Patients 50 yr or older
  • Patients signed informed consent

You may not qualify if:

  • Patients unable or unwilling to tolerate the scan until its completion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rambam Medical Center

Haifa, Israel

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Ora Israel, MD

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ora Israel, MD

CONTACT

972-4-8543009o_israel@rambam.health.gov.il

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 26, 2006

First Posted

December 27, 2006

Study Start

April 1, 2004

Last Updated

December 27, 2006

Record last verified: 2006-11

Locations

IL(1)